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Abstract
T11 Target structure (T11TS), a membrane glycoprotein isolated from sheep erythrocytes,
reverses the immune suppressed state of brain tumor induced animals by boosting the func-
tional status of the immune cells. This study aims at aiding in the design of more efficacious
brain tumor therapies with T11 target structure. We propose a mathematical model for brain
tumor (glioma) and the immune system interactions, which aims in designing efficacious
brain tumor therapy. The model encompasses considerations of the interactive dynamics of
glioma cells, macrophages, cytotoxic T-lymphocytes (CD8+ T-cells), TGF-β, IFN-γ and the
T11TS. The system undergoes sensitivity analysis, that determines which state variables
are sensitive to the given parameters and the parameters are estimated from the published
data. Computer simulations were used for model verification and validation, which highlight
the importance of T11 target structure in brain tumor therapy.
Introduction
In the rank of deadly form of tumors, adult primary malignant gliomas are the most common
primary brain tumors, occurring at a rate of five cases per 1,00,000 population per year [1].
The survival rate for malignant gliomas in the category of Grade-IV and Grade-III varies from
1 year to 3 years respectively [2, 3]. These high grade gliomas are not differentiable and are gen-
omically unstable. They have infiltrative behavior in their sequestered location beyond the
blood-brain-barrier (BBB). Therefore, conventional treatments including surgery, radiation
and chemotherapy often fails to control malignant gliomas, namely, Glioblastoma Multiforme
(GBM), which is the most common malignant glioma. Hence, there is a need for novel thera-
pies, namely, immunotherapy, in the hope that there is an increase in the survival rate of
the patients.
Using mathematical modeling as a viable tool, complex biological processes are studied. Be-
cause of the complexity and unpredictable pattern of the gliomas, mathematical modeling can
be extremely helpful in analyzing factors that may contribute to the complexity intrinsic in
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insufficiently understood glioma development process. Researchers have developed several
types of GBMmodels in recent years. The theoretical study of gliomas supported by experi-
mental finding has been classified mainly into two categories. While one group of researchers
study the temporal and spatiotemporal dynamics of glioma proliferation and invasion, the
other group formulates new therapies as a treatment, that may result in the survival of patients
with high grade gliomas.
Many mathematical models that describe the temporal or spatiotemporal dynamics of glio-
ma proliferation and invasion have been formulated. Through mathematical modeling, it is
possible to answer the diverse biological questions concerning the analysis of early GBM
growth, therapy effectiveness or even simulations in realistic brain structure. The mathematical
model developed by Swanson et al. quantifies the spatio-temporal proliferation and invasion
dynamics of gliomas in a 3D diffusion framework. Their model portrays the growth and exten-
sion of theoretical glioblastoma cells in a matrix that accurately describes the brain’s anatomy
to a resolution of 1 cubic millimeter. The model, not only has a significant resemblance with
the magnetic resonance imaging (MRI) of actual patients but also shows the distribution of dif-
fusely infiltrating cells [4–8]. Eikenberry et al., in their work, predicted patterns of tumor recur-
rence following various modes of therapeutic intervention through three-dimensional
mathematical model [9]. The first 3D model of solid glioma tumor growth, by developing a cel-
lular automata was done by Kansal et al., which realistically models the macroscopic behavior
of a malignant tumor using predominantly microscopic parameters [10]. Agent based model-
ing was also used to realistically simulate early GBM growth. The simulation provides insight
into the invasive nature of the GBM, its average invasion speed that drives the tumor to spatial
expansion [11]. Toma et al. [12] modeled brain tumor growth at the cellular level considering
the effect of microglial cells on the progression of malignant primary brain tumor with the help
of partial differential equations. The qualitative results presented in their work are in agree-
ment with in-vitro data.
One of the dominant aspects of malignant glioma growth is the invasion of brain, which pri-
oritizes the modeling of invasion dynamics. A theoretical framework of invasion of brain
tumor was introduced first by Tracqui et al. [13], followed byWoodward et al. [14] and Burgess
et al. [15]. Glioma invasion into a non-homogeneous brain structure was also studied by Swan-
son et al. [4] using the BrainWeb brain atlas. The authors simulate a realistic brain geometry
including fibre differentiation into grey and white matter and compare macrosopic simulation
data with clinical data obtained from the analysis of a series of one patient’s CT scans. Wurzel
et al. made a different approach and developed a cellular automation model, that simulates the
invasion, proliferation and death of tumor cells [16]. Kim et al. [17] presented a mathematical
model of glioblastoma multiforme evolution, its relative balance of growth and invasion. Their
model succeeded in providing explanation for the growth/invasion cycling patterns of glioma
cells in response to high/low glucose uptake in micro-environment in-vitro and suggests new
target for drugs, associated with miR451 upregulation.
Many GBM patients are subjected to glioma chemotherapy, tumor resection and radiation
therapy [18, 19] at some point during the course of their disease. The first modeling attempt of
glioma chemotherapy was done by Tracqui et al. [13], where the authors considered a patient
suffering from anaplastic astrocytoma treated with chemotherapy and modeled chemotherapy
as a spatially homogeneous equation of a reaction diffusion system. The model simulation
agreed with the clinical data derived from CT scans. Swanson et al. [6] proposed a modified
model for chemotherapy of GBM tumors, which assumes brain structure to be heterogeneous
(grey and white matter differentiation) that makes diffusion process space dependent. The sim-
ulations which were performed for realistic brain geometries, showed the decay of tumor cells
in grey matter due to sufficient drug delivery but failed to control the proliferation of glioma
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cells in the white matter. This model incorporates all the properties of the Tracqui model and
gave better understanding of the therapy effect.
Modeling the effects of various types of tumor resection were studied by many groups.
Woodward et al. [14] made the most noticeable study on resection modeling, where they used
the methodology of Tracqui et al. [13] (reaction diffusion equation). The system parameters
were estimated on the same patient’s CT scan of Tracqui et al. [13]. Several scenarios of GBM
resection were investigated by the authors and simulation of the model showed tumor recur-
rence. Swanson et al. [7] extended the work of Woodward et al. by considering inhomogeneous
brain structure. Numerical simulation of the model with different diffusion and growth rates of
the malignant glioma cells showed consistent recurrence of the resected tumors.
Many types of cancer, including brain tumor, have been subjected to systemic immunother-
apy by exogenous administration of immune cells or immunoregulatory factors with limited
success. Chakrabarty and Hanson formulated an optimal control problem of drug delivery to
brain tumor to minimize the tumor cell density and reducing the side effect of drugs using
Galerkin finite element method [20]. Bandara et al. proposed a mathematical model to support
the rational development of targeting strategies (in-silico) for efficiently transporting Paclitaxel,
an antimitotic drug across the blood-brain-barrier [21]. Kirkby et al. formulated a model of
glioblastoma, which predicts the effects of escalator of radiotherapy dose and reproduces ex-
tremely accurate clinical data [22]. Schmitz et al., through a cellular automaton model of brain
tumor studied heterogeneous tumors with both treatment sensitive and treatment resistant
cells. The authors investigated the monoclonal tumors, two-stream with resistant subpopula-
tion and multi-strain tumors with induced mutation and able to present survival time data
from each of these case studies [23]. Walker and Cook [24], through macroscopic model, de-
veloped a system of drug delivery to brain tumors, where the authors have assumed that the
drug is delivered to both normal and tumor tissue through vasculature system. By means of dif-
fusion and convection, the drugs penetrate the brain tissue across the vasculature and trans-
ported across the blood-brain-barrier and through the interstitial space. By assessing the effects
of changing parameters on drug delivery, they found an optimal treatment for convective drug
delivery to the center of the tumor. Kronik et al. [25] considered the interactive dynamics of cy-
totoxic T-Lymphocytes, brain tumor cells, major histocompability complex (MHC) class-I and
MHC class-II along with cytokines TGF-β and IFN-γ, where they have used computer simula-
tion for model verification and retrieving putative treatment scenarios. Their result suggests
that GBMmay be eradicated by new dose-intensive strategies or by significantly encouraging
the endogenous immune response or by T-cell infusion, as shown by their
mathematical model.
In this paper, we present a mathematical model for immunotherapy of brain tumor with
T11 target structure. The model describes a complex interaction involving glioma cells, macro-
phages, cytotoxic T-lymphocytes, the immuno-suppressive component TGF-β and the cyto-
kine IFN-γ. We use published data [26] to analyze the sensitivity of the system parameters and
to estimate their values. The model is then used to validate various immunotherapeutic scenar-
ios as observed in [26].
Materials and Methods
Biological Framework and Experimental Facts
The neurotoxic role of N-ethyl-N-nitrosourea (ENU) in inducing CNS (central nervous sys-
tem) tumors is well-established, but the assessment of a gradual transformation of the normal
cells to cancer cells has not been studied. In this experiment [26], the study elucidates the
changes on rate of survival, growth kinetics, immunological and histological parameters
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chronologically from (2nd–10th) months after induction of glioma in rats from neonatal stage.
Healthy newborn Druckray rats of both sexes were maintained in our institutional animal facil-
ity. Six animals in each group were weaned at 30 days of age and housed in separate cages at
22°C in a 12 h light/darkness cycle. Animals were fed autoclaved rat feed pellets and water ad li-
bitum. The experimental animals were grouped into five groups. (i) N: age-matched normal
healthy control. (ii) ENU: 3–5-days-old neonatal animals injected with ENU intraperitoneally
(i.p.) (iii) ET1: 5-month-old ENU-treated animals injected(i.p.) with the first dose of T11TS.
(iv) ET2: 5-month-old ENU-treated animals injected (i.p.) with the first and second doses of
T11TS at a 6-days interval. (v) ET3: 5-month-old ENU-treated animals injected (i.p.) with the
first, second, and third doses of T11TS at 6-days interval between each dose. Maintenance and
animal experiment procedures were strictly done as per the guidelines of the Committee for
the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government
of India and was monitored by the Institutional Animal Ethics Committee (IAEC), Post Grad-
uate Education and Research, Kolkata, India. Care was taken to minimize animal usage and
not inflicting pain to the animals in study. The control and experimental rats were euthanized
by over dose of Ketamine Hcl (80 mg/kg body wt, route: intramuscular). The Institutional Ani-
mal Ethics Committee (IAEC), Post Graduate Education and Research, Kolkata, India, specifi-
cally approved this study. Furthermore, an attempt was made to investigate the
immunomodulatory and antitumor properties of sheep red blood cells (SRBCs), glycopeptide
known as T11 target structure (T11TS).
3–5 days old Druckray rats of both sexes were glioma induced by intraperitoneal (i.p.) injec-
tion of ENU. 2nd, 4th, 6th, 8th and 10th months of rats after brain tumor (glioma) induction
were sacrificed to study tumor growth kinetics and a gamut of immunological parameters like
rosette technique of lymphocytes and phagocytosis peripheral macrophages and polymorpho-
nuclear neutrophil (PMN). Survival studies were done from the different groups of animals.
The survival study after ENU was injected included observations, which was done by register-
ing the total number of days an individual animal survived and the mean survival time in each
group. The survival rate of animals were also recorded after 2nd, 4th, 6th, 8th and 10th month of
ENU induction.
Proliferation index and the fluorochrome uptake studies were performed at an interval of
2nd month up to 10th month in ENU induced animals. Portions of tumor susceptible areas
from all the groups of rats were taken as samples of primary explant technique from which seri-
al passages were made to obtain a steady culture from which the experiments were performed.
Splenic macrophages were separated by adherent technique and polymorphonuclear cells
(PMN) separated by density gradient with percoll were subjected to nitroblue tetrazolium
assay to determine the phagocytic capacity of the individual cells in different groups. For evalu-
ating ENU induced cytotoxicity, cytolytic-asssays of splenic lymphocytes (SL) were performed
for HO-33342 release in the different groups of rats. Tumor cells (a steady glioma tumor line,
syngenic in nature) were tagged with HO-33342 fluorochrome dye (total incorporation) for 15
minutes at 37°C and the excess untagged dye was washed off. Fluorochrome released due to
target lysis was measured in a spectrofluorimeter.
Immunological findings have been strongly correlated with the histological findings. Ad-
ministration of the T11TS in ENU treated animals demonstrated the anti-neoplastic activity in
a dose dependent manner, as evidenced through the conversion of neoplastic glial cytopatholo-
gy to normal glial features. After 6 months of ENU induction, Grade-IV oligodendroglioma
was observed with mitotic figure, giant cells and a minimum intercellular space. Following the
10th month after ENU administration, the histological observation of brain sections showed a
ribbon like appearance of closely packed dividing cells, degenerative fibrils, oligodendroglioma
Grade-IV, mixed glioma. The 1st dose of the T11TS fraction shows reduced glioma cells due to
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apoptotic death. Reversion of neoplastic glioma features to normal glioma features was ob-
served following the 3rd dose of the T11TS fraction.
Model Formulation
The aim of the mathematical model is to yield a simplified version of the complicated biological
processes. The analytical power of the model can be greatly enhanced by deliberately isolating
the crucial forces in the system and neglecting the secondary effects. Our mathematical model
describes the effect of interactions between glioma cells (brain tumor cells) and the immune
system, which includes macrophages, CD8+ T-cells, TGF-β and IFN-γ. The model focusses on
the role of T11 target structure (T11TS) along with immune system as immunotherapy to
brain tumor, with the aim to simulate and thus evaluate possible therapeutic scenarios.
As the brain tumor (glioma) grows in size, it starts secreting immune suppressive factors
like Transforming Growth Factor-β (TGF-β), Prostaglandin E2(PG-E2), Interleukin-10(IL-10),
etc. These factors cross the blood-brain-barrier (BBB) and reach the peripheral immunocytes,
making them functionally inactive, so there is an overall immune suppressive state, helping in
the growth of the tumor. The tumor antigens also cross the BBB making the lymphocytes spe-
cific for the tumor antigens, that is, they will attack the glioma cells once they encounter. At
this juncture, when T11 Target Structure (T11TS) is injected intra-peritoneally, it activates the
systemic lymphocytes and also the macrophages. The activated macrophages cross the BBB
and enter the brain to attack the glioma cells and kill them by phagocytosis. The lymphocytes
once activated by T11TS enter the nearest lymph-node and crosstalk with macrophages which
present them as tumor antigens, making them specific for the killing of glioma cells. Both CD4
+ and CD8+ T-lymphocytes now can cross the large blood barrier at an increased number.
They now crosstalk with the macrophages within the brain, which again present them as a
tumor antigens. The macrophages and the lymphocytes after their crosstalk secrete various cy-
tokines which are conducive for the elimination of glioma cells. The macrophages and the lym-
phocytes, which are now activated and armed for glioma killing, eliminates glioma cells by
apoptosis. A schematic diagram depicting the above mentioned biological scenario is shown in
Fig 1.
In our model we consider a simplified version of the schematic diagram. Our goal is to for-
mulate a mathematical model which allows sufficient complexity so that the model may quali-
tatively generate the tumor growth pattern, while it simultaneously maintains sufficient
simplicity for analysis. The model we propose is a system of five non-linear ordinary differen-
tial equations (ODEs), to characterize the dynamics of the interaction between the glioma cells
(G) and different immunological components, namely, macrophages (M), cytotoxic T-lympho-
cytes or CD8+T cells (CT), TGF-β (Tβ), IFN-γ (Iγ) and the external anti-tumor agent T11TS
(Ts).
Dynamics of Glioma Cells. The dynamics of glioma cells is given by
dG
dt
¼ r1G 1
G
Gmax
 
 1
Tb þ e1
 !
ða1M þ a2CTÞ
G
Gþ k1
 
ð1Þ
We assume that in the absence of immune system glioma cells follow logistic growth, given by
the first term of the Eq (1); r1 is the intrinsic growth rate of glioma cells and Gmax is its carrying
capacity, that is, the maximal tumor cell burden. The second term of the Eq (1) shows how gli-
oma cells are eradicated by the macrophages and CD8+T cells at the rates α1 and α2 respective-
ly. It is also assumed that the elimination of the glioma cells by macrophages and CD8+T cells
are proportional to both G, M and G, CT respectively, with saturation for large G. Michaelis-
Menten term is being incorporated to bring out the accessibility of the glioma cells to
Tumor Abrogation with T11 Target Structure
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Fig 1. Schematic diagram. The figure shows the dynamics between brain tumor and the immune components, namely, macrophage, microglia, CD4+ T
cells, CD8+ T cells, dendritic cells, TGF-β, IFN-γ and the immunotherapeutic agent T11 target structure.
doi:10.1371/journal.pone.0123611.g001
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macrophages and CD8+T cells, implying that the effect of macrophages and CD8+T cells effi-
cacy follow Michaelis-Menten saturation dynamics, k1 being the half saturation constant. The
term 1
Tbþe1 is the major immunosuppressive factor for the activity of both the macrophages and
CD8+T cells, e1 being the Michaelis constant.
Dynamics of Macrophages. Dynamics of macrophages (M) is described by the Eq (2):
dM
dt
¼ r2M 1
M
Mmax
 
þ a1
Ig
k4 þ Ig
 !
1
Tb þ e2
 !
 a3
G
Gþ k2
 
M ð2Þ
Since, the macrophage growth pattern is not evident from existing literatures, we assume that
the macrophages grow logistically (in absence of glioma cells) with intrinsic growth rate r2 and
carrying capacityMmax (given by the first term of the Eq (2)). The second term in Eq (2) shows
the activation of macrophages by IFN-γ at a rate a1, k4 being the half saturation constant, im-
plying the presence of Michaelis-Menten saturation dynamics. At the same time, the term 1
Tbþe2
interrupts the activity of macrophages, it is a degradation term with saturation constant e2. The
third term gives the rate of immuno-induced macrophage death by malignant glioma cells at
the rate α3, k2 being the half saturation constant standing for the accessibility of glioma cells
to macropahges.
Dynamics of CD8+ T Cells. CD8+ T cell dynamics is given by
dCT
dt
¼ a2G
k5 þ Tb
 m1CT  a4
G
Gþ k3
CT ð3Þ
The first term in the Eq (3) represents the recruitment term of CD8+T cells which occurs due
to the direct presence of malignant glioma cells, a2 being the antigenicity of the glioma cells
which triggers an immune response in the host. The immunosuppressive response by TGF-β
puts limitation to the recruitment level, k5 being termed as the inhibitory parameter. μ1 is the
rate of loss of CD8+T cells due to inflammatory reaction in the brain. The last term in Eq (3)
represents the clearance of CD8+T cells by the glioma cells at a rate α4, k3 being the half
saturation constant.
Dynamics of the Cytokine TGF-β. Experimental evidence [27] suggests that TGF-β is
produced in a small quantity when production of glioma cells is small but it gets ample nutrient
from the neighboring tissue. But when glioma cell production grows sufficiently large resulting
in lack of oxygen and space, it starts producing TGF-β to stimulate angiogenesis and to destroy
immune response for tumor growth [28]. Eq (4) describes the dynamics of TGF-β:
dTb
dt
¼ s1 þ b1G m2Tb ð4Þ
The first term in Eq (4) represents the constant source term of TGF-β and the second term is
the source term which is proportional to the glioma size, b1 being the release rate per glioma
cells. The last term is the degradation of TGF-β at a constant rate μ2.
Dynamics of the Cytokine IFN-γ. Eq (5) represents the dynamics of IFN-γ:
dIg
dt
¼ b2CT  m3Ig ð5Þ
IFN-γ activates the macrophages, which are capable of destroying the glioma cells. We assume
that CD8+T cells is a source of IFN-γ [29] given by the first term of the Eq (5). The second
term shows the degradation of IFN-γ at a constant rate μ3.
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After the administration of immunotherapeutic agent T11TS, which activates different
immunocytes including macrophages, CD8+ T cells, we assume that these doses of T11TS will
have an effect on the cell count of macrophages and CD8+ T cells [26]. In mathematical terms,
we represent the administration of doses of T11TS by Dirac Delta function as input δ(t − τ),
where δ(t − τ) = 1, t = τ and 0, elsewhere. Three doses of T11TS were administered in the sys-
tem, the first one in the 7th month (210th day = τ1), followed by an interval of 6 days [26], that
is, in the 216th day (τ2) and 222
nd day (τ3).
The interactions of immune system, the dynamics of glioma cells and T11TS bringing to-
gether, leads to the following coupled non-linear ODEs:
dG
dt
¼ r1G 1
G
Gmax
 
 1
Tb þ e1
 !
ða1M þ a2CTÞ
G
Gþ k1
 
dM
dt
¼ r2M 1
M
Mmax
 
þ a1
Ig
k4 þ Ig
 !
1
Tb þ e2
 !
 a3
G
Gþ k2
 
M þ Ts
X3
i¼1
dðt  tiÞ
dCT
dt
¼ a2G
k5 þ Tb
 m1CT  a4
G
Gþ k3
CT þ Ts
X3
i¼1
dðt  tiÞ
dTb
dt
¼ s1 þ b1G m2Tb
dIg
dt
¼ b2CT  m3Ig
ð6Þ
with initial conditions
Gð0Þ ¼ G0  0; Mð0Þ ¼ M0  0; CTð0Þ ¼ CT0  0; Tbð0Þ ¼ Tb0  0; Igð0Þ ¼ Ig0  0:
Approaches to the estimation of system parameters
Estimating parameter values for the constructed mathematical model is one of the hardest
challenge which a modeler faces. Various techniques are approached to simplify the process.
Sensitivity analysis is one such tool which simplifies the process of parameter estimation into
several stages that are easier to solve. By using the sensitivity analyzing technique, the parame-
ters which are less sensitive as well as unidentifiable are categorized. The set of highly sensitive
parameters, which has been reduced to a tractable size, can be estimated from the available
experimental data.
The sensitivity analysis
In our model, we have 23 parameters, for which we need to determine its sensitivity and rank
the parameters with respect to their identifiability. The sensitivity graph obtained using the
codemyAD, developed by Prof. Martin Fink [30], is shown in the Fig 2. To quantify the sensi-
tivity from the figure, we calculate the sensitivity coefficient by non-dimensionalizing the sensi-
tivity functions and computing L2 norm of the resulting functions, given by
Cij ¼

 @ui@qj
qj
maxðuiÞ


2
2
¼
Z tf
t0
 @ui@qj
qj
maxðuiÞ

2
dt ð7Þ
After comparing and ranking the sensitivity function we can sort the most sensitive parameters
(in descending order) to the least ones as shown in the bottom panel of Fig 2. We next define
Fisher’s information matrix F = ST S. We compute the normalized sensitivity function matrix S
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using automatic differentiation [30]. The numerical rank of ST S was computed to be 9 (taking
square root of machine precision epsilon  = 10−8). We next use the QR factorization technique
with the column pivoting which is implemented in the MATLAB routine qr, [Q,R,P] = qr(F).
This method determines a permutation matrix P such that FP = QR (QR being the factorization
of FP). The indices in the first k columns of P, identify the k parameters that are most estimable.
Our case yields the ordering [r1, b1, r2, α1, μ1, α2, α4, μ2, α3]
T, that is, out of the 23 parameters,
only the first nine ranked parameters are the most identifiable and sensitive parameters. Please
note that, we will also estimate the parameter values a1 and k5 from the available data as we are
unable to get them from any other sources. Since, they are not sensitive, their estimated values
will not affect the dynamics of the system much.
The estimation of parameters
The analysis and behavior of a mathematical model, to describe a given system depends on the
system parameters. After identifying the most sensitive parameters, we now estimate the value
of the system parameters in the following manner:
TGF-β has a hepatic half life of 2.2 minutes [31]. However, the actual brain TGF-β will have
a slower decay rate because of its distance from the liver and its necessity to pass through the
Fig 2. Relative sensitivities of the parameters using automatic differentiation. From the top panel figures, it is observed that the parameters r1, α1, α2, r2,
α3, μ1, α4, b1, μ2 are sensitive with respect to the malignant glioma cells. The observation window is [0, 1000] and the sensitivity of a parameter is identified by
the maximum deviation of the state variable (along y-axis) and it also identifies the time intervals when the system is most sensitive to such changes. The
bottom panel gives the sensitivity quantification by calculating sensitivity coefficient through L2 norm.
doi:10.1371/journal.pone.0123611.g002
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blood-brain-barrier (BBB). This time was estimated to be 6 minutes [4], which is in hours
0.1 hours. Therefore, the decay rate is given by, m2 ¼ log2e0:1h ¼ 6:931471h1  6:93 h1.
In the Cerebral Spinal Fluid (CSF) of a glioblastoma patient, Peterson et al. [32] found the
concentration of TGF-β to be 609 pentagram (pg)/ml. We assumed the volume of CSF to be
150 ml. Since, there is a production of the tumor in a healthy individual, we obtain at steady
state, s1 − μ2 Tβ = 0, which implies s1 ¼ m2Tb ¼ 6:93h1  60:9 pgml 150 ml ¼
63305:55 pg h1  6:3305 104 pg h1 (in a healthy person the concentration of TGF-β is
10 times less than a glioblastoma patient).
For patients suffering from GBM, the mean level of cytokine TGF-β is 609 pg(ml)−1 = 609
pg(ml)−1 × 150 ml = 91350 pg [32]. Using the equation at the steady state, we have,
b1 ¼
m2Tb  s1
G
¼ 6:93 h
1  91350 pg 63305:55 pg h1
1011
¼ 0:000005697 pg h1cell1  5:70 106cell1pg h1:
The median half life of IFN-γ is found to be 0.283 days = (24 × 0.283) h = 6.792 h 6.8 h
[33]. Therefore, the hourly degradation of IFN-γ is given by
m3 ¼
log e2
6:8 h
¼ 0:693
6:8 h
¼ 0:101933409h1  0:102h1:
The production rate of IFN-γ by a single CD8+T cell, b2 is obtained (at the steady states) by
b2 ¼
m3Ig
CT
¼ 0:102h
1  200 pg=ml
2 105 cells=ml ¼ 0:000102 pg cells
1h1 ¼ 1:02 104 pg cells1h1
where 200 pg ml−1 of IFN-γ is reported in Kim et al. [34] and we assume 2 × 105 CTL ml−1.
The range for antigenicity of glioma cell (a2) is taken to be (0–0.5) obtained from Rosenberg
et al [35]. The half life of CD8+T cells is reported to be 3.9 days [36], therefore the estimated
hourly death rate μ1 is given by
m1 ¼
log e2
ð3:9 24Þ h  0:0074 h
1:
Activated CD8+T cell eradicates (0.7 -3) target cells per day [37]. Assuming that a CD8+T
cells kills 2.5 target cells per day, the rate is calculated to be 2:5
24
 0:1042 cells h−1. This experi-
ment was done with 5 × 105 glioma cells/ml in a separated culture disc [26]. The rate at which
activated CD8+T cells kill the glioma cells is estimated to be 0.1739 h−1 [26]. Therefore, we get
a4
G
Gþ k3
¼ 0:1042 h1 ) k3 ¼ 3:34452 105cells:
FromMukherjee et al. [26] (namely, Fig 3, page 329), we obtain the cell proliferation index
of glioma cells, before and after the administration of T11 target structure. It is observed that
there is a steep increase of cell proliferation index when 2nd, 4th, 6th months old ENU injected
animal brain cells, whereas in the 8th and 10th months, the increase is not very significant com-
pared to previous months. We obtain the cell-count, starting from 0th month till the 10th
month (6 data-points) and these, we consider to be the growth of glioma cells in the absence of
the immune system. The parameters to be estimated with these 6 data-points are r1 and Gmax.
To start the estimation process, the initial values of the parameters are chosen arbitrary (within
meaningful biological range). We use the least square method to minimize the sum of the resid-
ual, to obtain the estimated values of the system parameters r1, Gmax. In practice, we use the
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MATLAB function fminsearch to estimate the parameter values. The estimated values of r1
and Gmax are found to be respectively, 0.01 h
−1 and 8.8265 × 105 cells. Fig 3A shows the best fit
estimate for the model parameters r1 and Gmax. Next we add 3 more data points from the glio-
ma cell proliferation index obtained after receiving 3 doses of T11TS (see Fig 3, page 329 of
[26]), which shows a significant decrease in the cell count. We now consider the overall 9-data
points reflecting the dynamics of glioma cells and the immune system (including the immuno-
therapy of T11TS). The same process is repeated and we estimate the following parameters: r2
= 0.3307, a1 = 0.1163, α1 = 1.5, α3 = 0.0194, α4 = 0.1694, k5 = 2 × 10
3. Fig 3B shows the best fit
estimate for the model parameters r2, a1, α1, α3, α4 and k5. Please note that the whole estimation
process using the method of least squares is done by non-dimensionalizing the proposed
model. The non-dimensionalized values obtained are then converted back to the
actual parameters.
We have estimated the intrinsic growth rate (r1), carrying capacity of glioma cells (Gmax),
killing rate of macrophage (α1) as 0.01 h
−1, 8.8265 ×105 cells, 1.5 h−1 respectively, by fitting
model predictions from the result of Mukherjee et al. [26]. We took the value of e1 from Peter-
son et al. [32], which is the order of magnitude of the base line. The term is multiplied by the
volume of CNS, given by e1 = 150 ml × 60.9 pg/ml = 9135 pg 104 pg. The value of k1 (half sat-
uration constant) is 2.7 × 104 cells [26].
Activated CD8+T cell kills the target cells (0.7–3) per day, reported by Wick et al. [37]. The
rate of the mean value of two target cells per day is given by 2:4cells
24 h
= 0.1 cells/h. At the time of ex-
periment, they have taken target cells 5 ×105 cells/ml in 2 ml. wells. We have already mentioned
that the value of k1 have been taken from [26], which we need for the calculation of α2 (killing
rate of CD8+ T cells). The value of k1 to be taken as 2.7 × 10
4 cells/ml and multiplied by the vol-
ume of the well and then substituting the values into a2
G
Gþk1 ¼ 0:09167 h
−1) α2 = 0.11642 h−1
 0.12 h−1.
We have estimated the values of the growth rate (r2) of macrophages, the activation rate (a1)
of macrophages due to interaction with the IFN-γ and elimination term (α3) of the macro-
phages due to interaction with glioma cells are 0.3307 h−1, 0.1163 h−1 cells.pg and 0.0194 h−1
respectively. We took the value ofMmax (the carrying capacity of macrophages) is 10
6 cells
from the experimental value of Gutierrez et al. [38].
Fig 3. System parameter estimation by the method of least squares. Six data points are used to estimate the parameters r1 (glioma growth rate) and
Gmax (carrying capacity) in absence of immune system. The left panel A shows the best fit curve for the estimation of the parameters r1 andGmax. The
parameters r2, a2, α1, α3, α4 and k5 are estimated by using nine data points obtained during immunotherapy by T11TS, the right panel B showing the curve of
best fit.
doi:10.1371/journal.pone.0123611.g003
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The half saturation of IFN-γ was obtained from the half saturation of IFN-γ during the acti-
vation of macropahges [39], which multiplied by the volume of Central Nervous System, 150
ml. Therefore, k4 = 70 pg/ml × 150 ml = 10500 pg = 1.05 × 10
4 pg. Also, we took the value of e2
(the dependence of CD8+T cell efficiency on TGF-β) to the order of magnitude of the base line
60.9 pg/ml. from [32], which multiplied by the volume of CNS 150 ml. Therefore, e2 = 60.9 pg/
ml × 150 ml = 9135 pg 104 pg. By the experiment on a separate culture disc by Mukherjee
et al. [26], we took the value of k2 (half saturation constant) as 2.7 × 10
4 cells.
All the parameter values are put in tabular form (see Table 1).
Results
The model, given by (Eq 6), is subjected to numerical simulation for retrieving potential thera-
peutic effects using T11TS. The aim of the numerical simulation is to show what this model
would predict under different experimental scenarios, similar to reported in Mukherjee et al.
[26]. These simulations explain some of the reported experimental observations.
Before T11TS Administration
Figs (4–6) show the dynamics of the three state variables, namely, malignant glioma cells, mac-
rophages and CD8+ T-cells before the administration of T11TS. From the figures, it is clear
that the body’s own defence mechanism fails to control the growth of malignant glioma cells.
As observed in Fig 4A, there is a steep growth of malignant glioma cells for 180 days (6
Table 1. Parameter values used for numerical simulations.
Parameters Description Values Units Source
r1 growth rate of glioma (tumor) cells 0.01 h
−1 Estimated
Gmax carrying capacity of glioma (tumor) 8.8265 × 10
5 cell Estimated
e1 Michaelis Menten constant 10
4 pg [32]
α1 kill rate of macrophage 1.5 pg.h
−1 Estimated
α2 kill rate of CD8+ T cells 0.12 pg.h
−1 Estimated
k1 half saturation constant 2.7 × 10
4 cell [26]
r2 growth rate of Macrophages 0.3307 h
−1 Estimated
Mmax carrying capacity of Macrophages 10
6 cell [38]
a1 activation rate of Macrophages 0.1163 cell.h
−1 Estimated
k4 half saturation constant 1.05 × 10
4 pg [39]
e2 Michaelis Menten constant 10
4 pg [32]
α3 death rate of Macrophage 0.0194 h
−1 Estimated
k2 half saturation constant 2.7 × 10
4 cell [26]
a2 antigenicity of glioma (tumor) 0–0.5 h.pg
−1 [35]
k5 inhibitory parameter 2 × 10
3 pg Estimated
μ1 natural death of CD8+ T cells 0.0074 h
−1 Estimated
α4 death rate of CD8+ T Cells 0.1694 h
−1 Estimated
k3 half saturation constant 3.34452 × 10
5 cell Estimated
s1 constant source of TGF-β 6.3305 × 10
4 pg.h−1 Estimated
b1 release rate per glioma cell 5.70 × 10
−6 pg.cell−1.h−1 Estimated
μ2 natural death of TGF-β 6.93 h
−1 Estimated
b2 release rate per CD8+T cell 1.02 × 10
−4 pg.cell−1.h−1 Estimated
μ3 degradation of IFN-γ 0.102 h
−1 Estimated
doi:10.1371/journal.pone.0123611.t001
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months) and then the proliferation of glioma cells becomes slow and achieves a state of satura-
tion. The cell count did not vary to a great extent between (240–300) days (between 8th and
10th months), which is in good agreement, when compared with the tumor cell proliferation
index of ENU injected animal brain cells (see Fig 4B, namely, E2, E4, E6, E8, E10), counted on
2nd, 4th, 6th, 8th and 10th months respectively. The progressive increase of glioma cell popula-
tion indicates initiation of uncontrolled cell division. The process of gradual changes from nor-
mal to neoplastic stage and the ultimate establishment of intracranial neoplasm occurs during
this period, which implies that the probability of the survival rates of the rats decreases during
this period [26].
Fig 4. Glioma cell dynamics without T11 target structure (T11TS). The left panel A shows the growth of malignant glioma frommodel simulation and the
right panel B gives the experimental data showing glioma cell proliferation index (N to E10).
doi:10.1371/journal.pone.0123611.g004
Fig 5. Dynamics of Macrophages before T11 target structure (T11TS) administration. The left panel A gives the model simulation showing the decrease
in the cell count of macrophages and hence in its phagocytic activity. The right panel B gives the experimental data showing phagocytic activity of
macrophages (N to E10).
doi:10.1371/journal.pone.0123611.g005
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Fig 5A shows the dynamics of macrophage behavior before the administration of T11TS.
From the figure, we observe that the cell count of macrophages decreases from its initial value
to a significant level in two months (60 days); then a gradual decrease follows till the lowest
value is reached in the 4th month (120 days); after that there is a slight increase in the number
of macrophages in the 6th (180 days), 8th (240 days) and 10th (300 days) months respectively
and then, it reaches a steady state value. This means that the phagocytic activity of the macro-
phages reduces drastically in the first two months of tumor progression without T11TS, the
maximum decrease occurring in the 4th month (see Fig 5B), which may be due to the decrease
in the reactive oxygen production [26]. But, there is a slight increase in the macrophage medi-
ated phagocytosis in the 6th, 8th and 10th months, which may be interpreted as a macrophage
resistance against the malignant glioma cells.
Fig 6A shows the dynamics of CD8+ T cells and it is observed from the figure that the cell
count increases gradually till 180 days (till the 6th month) and then, there is a sharp decline,
which points to the fact that though T-lymphocytes tries to counterattack the glioma cells, its
cytotoxic efficacy sharply decreases in the 8th month with maximum decrease observed in the
10th month (see Fig 6B). This may be due to the action of the inhibitory cytokine feedback
mechanism (say, TGF-β) exerted by the fully grown tumor mass [40].
After T11TS Administration
Fig 7 shows the dynamics of malignant glioma cells after the administration of T11TS. The first
dose of T11TS was injected after 7 months on ENU injected animals, which shows a significant
decrease in the cell count of malignant glioma cells. This agrees with the cell proliferation
index of glioma cells obtained from experiment (see Fig 7D for E10 to ET1). This decrease may
be interpreted as the increase of total survival period. A sharp increase of glioma cells is noticed
after 250 days. Here, we predict that if the 2nd dose of T11TS is not administered soon, tumor
resurgence will occur, which tries to reach a steady state as seen before T11TS administration
and this is evident from Fig 7A. The second dose, which is administered after 6 days, does not
exhibit such a profound effect but still there is a decline in the cell count of glioma cells (Fig
7B). After another 6 days, when the third dose of T11TS is administered, the cell count goes to
Fig 6. Dynamics of CD8+ T cells before administration of T11TS. The left panel A gives the model simulation showing the attempt and failure of CD8+ T
cells to counter-attack the malignant glioma cells. The right panel B gives the experimental data showing the decrease in cytotoxic efficacy (N to E10) of CD8
+ T cells.
doi:10.1371/journal.pone.0123611.g006
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zero, thereby succeeding in eradicating the malignant glioma cells (Fig 7C). The simulation
agrees with the experimental data as shown in Fig 7D (ET1, ET2, ET3).
Enhanced phagocytic activity occurs after the first dose of T11TS (administered on 210th
day) hinting at the probable arming of the macrophages against the malignant glioma cells.
The cell count of macrophages increases significantly, thereby facilitating high macrophage
stimulation for malignant glioma cell phagocytosis. However, the 2nd and 3rd doses (adminis-
tered on the 216th and 222nd day respectively) do not have significant stimulation when com-
pared to the first dose (Fig 8). This dynamics of macrophages after the doses of
immunostimulatory agent T11TS suggests lymphokine mediated activation of macrophages
may occur in a dose dependent manner, which agrees with the experimental data obtained
from [26] (see inset Fig 8 for ET1, ET2, ET3).
The cytotoxic efficacy of CD8+ T cells take an upper hand after the 1st and 2nd dose of
T11TS, indicating significant lymphocyte proliferation and activation but most significant in-
crease in the cell count of CD8+ T cells and hence improvement in the cytotoxic activity of the
lymphocytes (CD8+ T cells), is observed after the administration of the 3rd dose of T11TS (Fig
9), which actually helps in eliminating malignant glioma cells. This is in good agreement with
the experimental data (see inset Fig 9 for ET1, ET2, ET3) obtained from [26].
TGF-β, the immunosuppressive factor secreted by the brain tumor increases sharply be-
tween (0–180) days (Fig 10A), which suppresses the activation and proliferation of
Fig 7. Malignant glioma dynamics after the doses of T11 target structure. Through model simulation, the three figures (A,B,C) show the behavior of
malignant glioma cells after the (A) first dose (B) second dose (C) third dose of T11TS, the first being administered in the 7th month (210th day), followed by
the other two at an interval of 6 days. The fourth figure (D) shows the experimental data of proliferation index of glioma cells after T11TS administration (N to
ET3).
doi:10.1371/journal.pone.0123611.g007
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Fig 8. Macrophage stimulation increases with the doses of T11TS.Model simulation shows significant stimulation of macrophages after the first dose,
when compared with the next two doses. The inset figure represents the experimental data showing increase in phagocytic activity of macrophages.
doi:10.1371/journal.pone.0123611.g008
Fig 9. Dynamics of CD8+ T-cells after the administration of T11 target structure.Optimal increase in the cell count and therefore efficacy of CD8+ T
cells is observed after the 3rd dose of T11TS. The inset figure shows the experimental data of cytotoxic efficacy.
doi:10.1371/journal.pone.0123611.g009
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macrophages and CD8+ T cells, resulting in the steep growth of the glioma cells in the 2nd, 4th
and 6th months (0–180 days) (see Fig 4A). But, this down-regulation is somewhat balanced by
IFN-γ, which increase T-lymphocyte migration across blood-brain-barrier (BBB) [41] and also
upregulates MHC Class II on macrophages. But, without T11TS, IFN-γ fails to revive the im-
mune system to counter-attack the malignant glioma cells and degrades in approximately 2
months (Fig 10B). TGF–β, the immunosuppressive factor decreases significantly after the ad-
ministration of T11TS and the cytokine IFN-γ is stimulated, which activates the macrophages,
featuring its immunostimulatory and immunomudulatory effects (Fig 10C and 10D). Thus,
from the above observations, T11 target structure seems to clear the first step in its approach to
destroy malignant glioma cells.
Discussion
In the class of heterogeneous group of cancer, brain tumor or intracranial neoplasm is one of
the toughest challenges in the field of medical science. Despite multi-modal therapeutic efforts,
patient’s mean survival for Grade-IV tumor is only 9–12 months and 2 years for Grade-III tu-
mors [3]. Due to its unique anatomy and biology, conventional treatment strategies fails in ma-
lignant brain tumors (gliomas). Therefore, adaptation of different immunotherapeutic
Fig 10. Dynamics of TGF–β and IFN–γ. Before the administration of T11TS, TGF–β, the immunosuppressive agent, suppresses the activation and
proliferation of immune components with its increase (Fig. A) whereas IFN–γ degrades in 2 months, pointing out its failure to activate the immune system
(Fig. B). However, after the doses of T11TS, TGF–β decreases and immunostimulatory effect of IFN–γ increases (Fig. C and Fig. D).
doi:10.1371/journal.pone.0123611.g010
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strategies are required as an alternative modality of glioma treatment. T11 target structure, a
transmembrane glycopeptide of sheep red blood cells, when administered in experimentally in-
duced brain tumor (glioma) animals, was found to exert a profound immunopotentiatory effect
on peripheral immunocytes including lymphocytes and macrophages. One of the major advan-
tage of using T11TS as a therapeutic agent is its ability to overcomes BBB impermeability [26,
42]. Motivated by the fact that an efficacious therapeutic method is necessary, we analyze the
mentioned result using a mathematical model, whose parameters were estimated from pub-
lished experimental data.
Though the schematic diagram also shows interactions between brain tumor and the im-
mune system, namely, macrophages, CD8+ T-cells, CD4+ T-cells, TGF-β, IFN-γ, microglial
cells, dendritic cells etc., we have kept our model simple by choosing only five state variables.
The challenging part is to obtain the sensitivity of 23 system parameters and its estimation,
which has been done successfully. We know that the growth of glioma cells is a heterogeneous
process (which is stochastic in nature) but the details of progressive development (preclinical
development, which includes growth pattern and invasive nature) of the malignant glioma
cells is not the object of study here. In the present course of investigation, we are interested in
the know-how of the primary resistance offered by the immune system after the complete es-
tablishment of intracranial neoplasm (after ENU administration) and the subsequent dynamics
of the effect of immuno-stimulatory agent T11 target structure.
To examine potential approaches towards achieving glioma eradication with T11 target
structure as a potent immune stimulator, we develop a mathematical model involving immune
components, namely, macrophages, CD8+ T cells, TGF − β and IFN − γ. The sensitivity analy-
sis has been performed on the system parameters, which indicates r1 (growth rate of malignant
glioma cells) to be the most sensitive parameter. The consequent subset selection and parame-
ter identifiability set also contains r1, which has been estimated from pre-clinical rat experi-
ment of the growth of malignant glioma cells in absence of T11 target structure. Thus, if no
treatment is administered, the model predicts that the malignant glioma grows to a large size,
either at system’s carrying capacity or close to it. Inevitably, the untreated malignant brain
tumor will grow to its maximum size, since the natural immune response against it, is too
weak. After T11TS administration, the cytotoxic activity of CD8+ T-lymphocytes is greatly en-
hanced, indicating potentiation of intracranial immune responses. The macrophages also get
activated and there is an increase in the cell count, which felicitates the phagocytic activity of
macrophages so that the malignant glioma cells are eradicated. An important advantage of
local intro-tumoral infusion of T11TS is their mobility, which can penetrate through areas of
brain. This lowers the level of tumor produced TGF-β, which, in turn, improve the host’s im-
mune response to the malignant glioma cells.
The main conclusion of the present study is that our model emulates some of the the experi-
mental findings of Mukherjee et al. [26]. From the results obtained, we can say that the interac-
tion of T11 target structure plays an important role in T-cell and macrophage activation and
proliferation. While examining the dynamics of the model, two biologically important observa-
tion emerged. First, with the administration of T11 target structure, the glioma cell prolifera-
tion is controlled, which increases the survival rate of the animals. Second, with the increase in
macrophages and CD8+ T cell count after T11TS administration, our model predicts the in-
crease in phagocytic activity of macrophages as well as cytotoxic efficacy of the CD8+ T cells,
which is in good agreement with Mukherjee et al. [26]. The proposed model has the potential
to predict and quantify the doses of T11 target structure in other bigger animals (say, chimpan-
zee). Several other factors or variables, say microglia (a strong candidate for the clearance of
cells undergoing apoptosis) or dentric cell or CD4+ T-cells may be introduced in the model
and the corresponding dynamics may be studied, which may later be verified with the
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experimental data. We sincerely hope that immunotherapy with T11 target structure turns out
to be a promising therapeutic method and needs to be investigated on humans.
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